218 related articles for article (PubMed ID: 34156708)
21. Expression of B7-H3 and TIM-3 in gastric-type endocervical adenocarcinoma: prevalence, association with PD-L1 expression, and prognostic significance.
Sun Y; Zhou X; Lucas E; Chen L; Zhang H; Chen H; Zhou F
J Pathol Clin Res; 2024 Jan; 10(1):e345. PubMed ID: 37798754
[TBL] [Abstract][Full Text] [Related]
22. Contribution of tumour and immune cells to PD-L1 expression as a predictive biomarker in metastatic triple-negative breast cancer: exploratory analysis from KEYNOTE-119.
Cortes J; Winer EP; Lipatov O; Im SA; Gonçalves A; Muñoz-Couselo E; Lee KS; Schmid P; Tamura K; Testa L; Witzel I; Ohtani S; Hund S; Kulangara K; Karantza V; Mejia JA; Ma J; Jelinic P; Huang L; Pruitt SK; Emancipator K
J Pathol Clin Res; 2024 May; 10(3):e12371. PubMed ID: 38627977
[TBL] [Abstract][Full Text] [Related]
23. Discordance of PD-L1 expression in primary and metastatic ovarian high-grade serous carcinoma and its correlation with CD8 + tumor-infiltrating lymphocytes and patient prognosis.
Zhang T; Zhou X; Zhang X; Niu S; Chen H; Zhou F
Virchows Arch; 2023 Apr; 482(4):755-766. PubMed ID: 36806916
[TBL] [Abstract][Full Text] [Related]
24. The immune checkpoints CTLA-4 and PD-L1 in carcinomas of the uterine cervix.
Karpathiou G; Chauleur C; Mobarki M; Peoc'h M
Pathol Res Pract; 2020 Jan; 216(1):152782. PubMed ID: 31862202
[TBL] [Abstract][Full Text] [Related]
25. Tumor-associated CD204
Kawachi A; Yoshida H; Kitano S; Ino Y; Kato T; Hiraoka N
Cancer Sci; 2018 Mar; 109(3):863-870. PubMed ID: 29274107
[TBL] [Abstract][Full Text] [Related]
26. Looking past PD-L1: expression of immune checkpoint TIM-3 and its ligand galectin-9 in cervical and vulvar squamous neoplasia.
Curley J; Conaway MR; Chinn Z; Duska L; Stoler M; Mills AM
Mod Pathol; 2020 Jun; 33(6):1182-1192. PubMed ID: 32139873
[TBL] [Abstract][Full Text] [Related]
27. PD-L1/PD-1 Expression in Endometrial Clear Cell Carcinoma: A Potential Surrogate Marker for Clinical Trials.
Jin C; Hacking S; Liang S; Nasim M
Int J Surg Pathol; 2020 Feb; 28(1):31-37. PubMed ID: 31311367
[No Abstract] [Full Text] [Related]
28. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
[TBL] [Abstract][Full Text] [Related]
29. PD-L1 Expression in HPV-associated Versus HPV-independent Invasive Vulvar Squamous Cell Carcinoma.
Bui CM; Medeiros F; Azimpouran M; Venturina M; Balzer B
Int J Gynecol Pathol; 2024 Jul; 43(4):405-413. PubMed ID: 38303111
[TBL] [Abstract][Full Text] [Related]
30. Programmed death-ligand 1 (PD-L1) expression in cervical intraepithelial neoplasia and cervical squamous cell carcinoma of HIV-infected and non-infected patients.
Brito MJ; Sequeira P; Quintas A; Silva I; Silva F; Martins C; Félix A
Virchows Arch; 2024 Mar; 484(3):507-516. PubMed ID: 37341812
[TBL] [Abstract][Full Text] [Related]
31. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
32. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
[TBL] [Abstract][Full Text] [Related]
33. Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas.
Reddy OL; Shintaku PI; Moatamed NA
Diagn Pathol; 2017 Jun; 12(1):45. PubMed ID: 28623908
[TBL] [Abstract][Full Text] [Related]
34. Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.
Cruz-Rico G; Avilés-Salas A; Popa-Navarro X; Lara-Mejía L; Catalán R; Sánchez-Reyes R; López-Sánchez D; Cabrera-Miranda L; Aquiles Maldonado-Martínez H; Samtani-Bassarmal S; Arrieta O
Pathol Oncol Res; 2021; 27():597499. PubMed ID: 34257548
[No Abstract] [Full Text] [Related]
35. The worsening impact of programmed cell death ligand 1 in ovarian clear cell carcinomas.
Matsuura H; Miyamoto M; Hada T; Ishibashi H; Iwahashi H; Kakimoto S; Suzuki R; Ito T; Suminokura J; Tsuda H; Takano M
Arch Gynecol Obstet; 2022 Dec; 306(6):2133-2142. PubMed ID: 35507079
[TBL] [Abstract][Full Text] [Related]
36. Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer.
Yoneda K; Kuwata T; Kanayama M; Mori M; Kawanami T; Yatera K; Ohguri T; Hisaoka M; Nakayama T; Tanaka F
Br J Cancer; 2019 Sep; 121(6):490-496. PubMed ID: 31388183
[TBL] [Abstract][Full Text] [Related]
37. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
[TBL] [Abstract][Full Text] [Related]
38. Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma.
Schoenfeld JD; Gjini E; Rodig SJ; Tishler RB; Rawal B; Catalano PJ; Uppaluri R; Haddad RI; Hanna GJ; Chau NG; Rabinowits G; Lorch J; Jo VY; Krane JF; Goguen LA; Annino DJ; Abdelrahman S; Lipschitz M; Margalit DN
Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):137-145. PubMed ID: 29960819
[TBL] [Abstract][Full Text] [Related]
39. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
[TBL] [Abstract][Full Text] [Related]
40. Expression and Significance of Immune Checkpoints in Clear Cell Carcinoma of the Uterine Cervix.
Zong L; Zhang Q; Zhou Y; Kong Y; Yu S; Chen J; Zhang Y; Xiang Y
J Immunol Res; 2020; 2020():1283632. PubMed ID: 32322590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]